Konstantin Balashov

Clinical Professor, Boston University Chobanian & Avedisian School of Medicine

Publications

  • Published 12/14/2024

    Pandey KS, Giles K, Balashov K, Macdonell R, Windsheimer J, Martinez M, Božin I, Raynaud S, Scaramozza M, Mokliatchouk O, Sun Z, Belviso N, Sato Y, Lin X, Okai A. Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study. Neurol Ther. 2025 Feb; 14(1):243-260. PMID: 39673658.

    Read at: PubMed

  • Published 11/21/2024

    Mao-Draayer Y, Bar-Or A, Balashov K, Foley J, Smoot K, Longbrake EE, Robertson D, Mendoza JP, Lewin JB, Everage N, Božin I, Lyons J, Mokliatchouk O, Bame E, Giuliani F. Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients. Adv Ther. 2025 Jan; 42(1):395-412. PMID: 39570545.

    Read at: PubMed

  • Published 10/21/2022

    Yadav SK, Ito N, Mindur JE, Kumar H, Youssef M, Suresh S, Kulkarni R, Rosario Y, Balashov KE, Dhib-Jalbut S, Ito K. Fecal Lcn-2 level is a sensitive biological indicator for gut dysbiosis and intestinal inflammation in multiple sclerosis. Front Immunol. 2022; 13:1015372. PMID: 36341389.

    Read at: PubMed

  • Published 5/28/2020

    Balashov K, Dhib-Jalbut S, Rybinnik I. Fibrinolysis induced clinical improvement in a patient with multiple sclerosis exacerbation. Mult Scler Relat Disord. 2020 Aug; 43:102225. PMID: 32505025.

    Read at: PubMed

  • Published 10/1/2016

    Balashov K. Imaging of Central Nervous System Demyelinating Disorders. Continuum (Minneap Minn). 2016 Oct; 22(5, Neuroimaging):1613-1635. PMID: 27740991.

    Read at: PubMed